Milvexian

Phase 3

Bristol-Myers Squibb Company (BMY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Oct '26

BMYPhase 3$126.6B

Milvexian Phase 3 Est. Readout

Milvexian• Ischemic Stroke; Ischemic Attack, Transient12,523

Oct 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Ischemic Stroke; Ischemic Attack, Transient

View Full Landscape

Drug Information

Target Indication

Ischemic Stroke; Ischemic Attack, Transient

Clinical Trial

NCT05702034

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BMY

Bristol-Myers Squibb Company

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

IpilimumabPhase 3

Prostatic Neoplasms, Castration-Resistant

BMS-986393Phase 3

Relapsed or Refractory Multiple Myeloma (RRMM)

NivolumabPhase 3

Recurrent Head and Neck Squamous Cell Carcinoma

Nivolumab and rHuPH20Phase 3

Clear Cell Renal Cell Carcinoma

Nivolumab 3 mg/kg IVPhase 3

Melanoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts